Topic: chronic obstructive pulmonary disease (COPD)
The dual PDE3/PDE4 inhibitor failed to beat placebo on a measure of lung function, wiping more than 30% off Verona’s share price.
At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.
Teva received FDA approval for a fully integrated digital rescue inhaler for patients with asthma and COPD, equipped with built-in sensors.
A pilot clinical study demonstrated how Kaia Health’s artificial intelligence-based smartphone app could reduce a patient’s COPD symptoms.
ResMed is acquiring Propeller Health in a $225 million deal to broaden the reach of its connected respiratory devices across all stages of COPD.
Bayer and Evotec partner Haplogen will work to identify new treatments, such as antivirals, for pulmonary diseases.
Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.
4D will use its AAV vectors to create therapies that insert genes that code for therapeutic proteins into human cells.
An FDA advisory committee panel voted against recommending premarket approval for PneumRx’s Elevair lung implant for patients with severe emphysema.